Dermira (NASDAQ:DERM) Upgraded by BidaskClub to Buy

BidaskClub upgraded shares of Dermira (NASDAQ:DERM) from a hold rating to a buy rating in a research report released on Wednesday, December 20th.

Other equities research analysts have also recently issued reports about the company. Needham & Company LLC reaffirmed a buy rating and set a $43.00 price target (down from $46.00) on shares of Dermira in a report on Tuesday, November 7th. Cantor Fitzgerald reissued a buy rating and issued a $45.00 target price on shares of Dermira in a research note on Monday, November 6th. Mizuho reissued a buy rating and issued a $43.00 target price (up from $40.00) on shares of Dermira in a research note on Thursday, September 7th. Guggenheim reissued a buy rating and issued a $30.00 target price on shares of Dermira in a research note on Thursday, December 14th. Finally, Leerink Swann reaffirmed an outperform rating and set a $41.00 price objective (down from $47.00) on shares of Dermira in a research note on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of Hold and an average target price of $41.00.

Dermira (NASDAQ:DERM) traded up $0.74 during trading on Wednesday, hitting $27.44. The company had a trading volume of 1,060,000 shares, compared to its average volume of 597,006. The company has a debt-to-equity ratio of 1.40, a current ratio of 4.68 and a quick ratio of 4.68. The company has a market cap of $1,140.00, a P/E ratio of -4.40 and a beta of 0.80. Dermira has a 1-year low of $21.35 and a 1-year high of $38.75.

In other news, CEO Thomas G. Wiggans sold 5,000 shares of the business’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $27.52, for a total value of $137,600.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Eugene A. Bauer sold 3,000 shares of the business’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $27.34, for a total value of $82,020.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 36,258 shares of company stock worth $985,873. Corporate insiders own 13.30% of the company’s stock.

Several large investors have recently added to or reduced their stakes in DERM. BNP Paribas Arbitrage SA increased its position in shares of Dermira by 2,220.7% in the second quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 3,975 shares during the last quarter. Quantbot Technologies LP increased its position in shares of Dermira by 75.4% in the third quarter. Quantbot Technologies LP now owns 5,371 shares of the biopharmaceutical company’s stock valued at $145,000 after acquiring an additional 2,309 shares during the last quarter. SG Americas Securities LLC increased its position in shares of Dermira by 66.8% in the second quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock valued at $160,000 after acquiring an additional 2,203 shares during the last quarter. Legal & General Group Plc increased its position in shares of Dermira by 40.9% in the second quarter. Legal & General Group Plc now owns 9,664 shares of the biopharmaceutical company’s stock valued at $281,000 after acquiring an additional 2,803 shares during the last quarter. Finally, Ardsley Advisory Partners acquired a new stake in shares of Dermira in the second quarter valued at about $291,000. 99.47% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Dermira (NASDAQ:DERM) Upgraded by BidaskClub to Buy” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://ledgergazette.com/2018/01/13/dermira-derm-upgraded-by-bidaskclub-to-buy.html.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply